PTC Therapeutics (PTCT) said late Wednesday the US Food and Drug Administration has accelerated approval of Kebilidi, the company's gene therapy for the treatment of aromatic L-amino acid decarboxylase deficiency.
The therapy, also called eladocagene exuparvovec-tneq, is for the treatment of children and adults across the full spectrum of the rare, life-shortening genetic deficiency, the company said.
Treatment centers have already been identified and surgeons already trained to administer the treatment, which is injected directly into the brain, the company said.
The drug received accelerated approval based on results of an ongoing clinical trial, the company said.
Shares of the company were up 5% in Wednesday's after-hours activity.
Price: 46.23, Change: +2.20, Percent Change: +5.00
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。